SCHEMBL1067232

SCHEMBL1067232

CCOC(=O)/C=C(\C)Oc1cccc(C)c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.46
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 1/20 0.43
MAPT P10636 5/20 0.42
GAA P10253 2/20 0.40
RAB9A P51151 3/20 0.40
KDM4E B2RXH2 2/20 0.40
NPC1 O15118 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 3/20 0.40
NLRP3 Q96P20 1/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1067236 1.00 POLB (0.46) POLBCYP3A4CYP2D6MAPTGAA
SCHEMBL1067235 1.00 POLB (0.46) POLBCYP3A4CYP2D6MAPTGAA
SCHEMBL1065610 0.88 TDP1 (0.46) POLBMAPTGAARAB9AKDM4E
SCHEMBL1065614 0.88 TDP1 (0.46) POLBMAPTGAARAB9AKDM4E
SCHEMBL1065611 0.88 TDP1 (0.46) POLBMAPTGAARAB9AKDM4E
SCHEMBL1063774 0.85 CYP1A2 (0.37) POLBCYP3A4CYP2D6MAPTGAA
SCHEMBL1063770 0.85 CYP1A2 (0.37) POLBCYP3A4CYP2D6MAPTGAA
SCHEMBL1063772 0.85 CYP1A2 (0.37) POLBCYP3A4CYP2D6MAPTGAA
SCHEMBL1067862 0.83 POLB (0.42) POLBCYP3A4CYP2D6MAPTGAA
SCHEMBL1067867 0.83 POLB (0.42) POLBCYP3A4CYP2D6MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 POLB 1255/4885CYP3A4 2098/4885CYP2D6 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.